Therefore, our study discovered a new anti-inflammatory mechanism of CYLD in sepsis-induced lung inflammatory responses and identified the CYLD-TRAF6/sNASP axis as a potential therapeutic target for treating sepsis-induced ALI. The gene discussed is TRAF6; the disease is Sepsis.